Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan

Jyotsna Mehta, Hongwei Wang, Jon P. Fryzek, Sheikh Usman Iqbal, Ruben Mesa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.

Original languageEnglish (US)
Pages (from-to)2368-2374
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

State Health Plans
Primary Myelofibrosis
Health Resources
Essential Thrombocythemia
Polycythemia Vera
Health Care Costs
Cost of Illness
Neoplasms
Delivery of Health Care
Costs and Cost Analysis
Health Insurance
Health Expenditures
Hospital Emergency Service
Inpatients
Outpatients
Databases

Keywords

  • Health resource utilization
  • Myeloproliferative disorders

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. / Mehta, Jyotsna; Wang, Hongwei; Fryzek, Jon P.; Iqbal, Sheikh Usman; Mesa, Ruben.

In: Leukemia and Lymphoma, Vol. 55, No. 10, 01.10.2014, p. 2368-2374.

Research output: Contribution to journalArticle

Mehta, Jyotsna ; Wang, Hongwei ; Fryzek, Jon P. ; Iqbal, Sheikh Usman ; Mesa, Ruben. / Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 10. pp. 2368-2374.
@article{a2abe8b8d6e54b85a113991cd933e1a4,
title = "Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan",
abstract = "Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.",
keywords = "Health resource utilization, Myeloproliferative disorders",
author = "Jyotsna Mehta and Hongwei Wang and Fryzek, {Jon P.} and Iqbal, {Sheikh Usman} and Ruben Mesa",
year = "2014",
month = "10",
day = "1",
doi = "10.3109/10428194.2013.879127",
language = "English (US)",
volume = "55",
pages = "2368--2374",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan

AU - Mehta, Jyotsna

AU - Wang, Hongwei

AU - Fryzek, Jon P.

AU - Iqbal, Sheikh Usman

AU - Mesa, Ruben

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.

AB - Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.

KW - Health resource utilization

KW - Myeloproliferative disorders

UR - http://www.scopus.com/inward/record.url?scp=84925326065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925326065&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.879127

DO - 10.3109/10428194.2013.879127

M3 - Article

VL - 55

SP - 2368

EP - 2374

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -